



Executive Summary

<http://simplefixrx-investors.com> – Invest in Better Health

Problem

Current GLP-1/GIP therapies for weight management rely on costly, invasive injections with adherence challenges, patient hesitancy, and supply chain issues.

Solution

FinalFixRx introduces the first-to-market, **needle-free nebulizer delivery system** for GLP-1/GIP therapies. This innovative approach improves patient comfort, convenience, and long-term adherence while reducing barriers to adoption.

Market Opportunity

The global GLP-1 obesity therapeutics market is projected to exceed **\$100B by 2030**. Early entry with a disruptive delivery method positions FinalFixRx for rapid adoption across providers, clinics, and weight-loss brands serving affluent patients.

Roadmap

- **Q3 2025:** Pilot study with 20 patients via 503A pharmacies.
- **Q4 2025:** Begin presales to targeted patients and clinics.
- **Q1 2026:** Full commercial launch with telehealth integration.
- **2026+:** Expansion to 503B/Pharma grade, AI-driven dosage tracking, and full peptide portfolio.

Financial Outlook

Targeting **180,000+ patients within 3 years**, with projected **\$770M+ revenue** and **\$218M net income** by Year 3, scaling to almost **\$3B in revenue** by Year 4.

Funding Ask & Use of Proceeds

We are raising **\$5 million** in growth capital to accelerate commercialization of FinalFixRx.

- **50%** – Sales & Marketing (clinic partnerships, patient acquisition)
- **20%** – Product Development & Regulatory (device optimization, clinical validation)
- **20%** – Operations & Telehealth Platform (scaling integrated care delivery)
- **10%** – Working Capital & Contingency

Partner with SimpleFixRx

Request Access to
Data Room

Schedule a Call

Fundraising effort is being conducted by [Zarrugh Consultancy LLC](#)

info@simplefixrx-investors.com

[1 \(888\) 470-5304](tel:18884705304)

